Seroconversion for Anti-melanoma differentiation-associated protein5 (Anti-MDA5) (Eng)
Article Sidebar
Main Article Content
Abstract
A sixty-six-year-old Thai female presented with progressive dyspnea and non-productive cough. She was diagnosed with MDA-5 dermatomyositis with rapidly progressive interstitial lung disease (RP-ILD) from UIP pattern in her high-resolution computed tomography-chest (HRCT-chest) and anti-MDA5 strongly positive in her myositis profile. After one year of treatment with steroid and immunosuppressive therapy, follow-up testing of anti-MDA-5 became negative in result.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
Lundberg, I. E. et al. Idiopathic inflammatory myopathies. Rev. Dis. Prim. 7, 86 (2021).
McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Rev. Rheumatol. 14, 290–302 (2018).
Nombel, A., Fabien, N. & Coutant, F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Immunol. 12, 773352 (2021).
Xie, H. et al. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review. Arthritis Rheum. 62, 152231 (2023).
Fiorentino, D., Chung, L., Zwerner, J., Rosen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. Am. Acad. Dermatol. 65, 25–34 (2011).
Hall, J. C. et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 65, 1307–1315 (2013).
Gono, T. et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49, 1713–1719 (2010).
Chen, F., Wang, D., Shu, X., Nakashima, R. & Wang, G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Int. 32, 3909–3915 (2012).
Ceribelli, A. et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Exp. Rheumatol. 32, 891–897 (2014).
Chen, Z. et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 65, 1316–1324 (2013).
Zuo, Y. et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology 59, 2829–2837 (2020).
Matsushita, T. et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. J. Dermatol. 176, 395–402 (2017).
Cao, H. et al. Clinical manifestations of dermatomyositis and clinicallyamyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res. 64, 1602–1610 (2012).
Sakamoto, S. et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Investig. 56, 464–472 (2018).
Xu, Y.-T. et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology 62, 397–406 (2023).
Sato, S., Kuwana, M., Fujita, T. & Suzuki, Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Rheumatol. 23, 496–502 (2013).
Jiang Z, Yao X, Tang F, Ma W. Case report: Successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib. Immun Inflamm Dis. 2023 Jun;11.
Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical Manifestations of Dermatomyositis and Clinically Amyopathic Dermatomyositis Patients With Positive Expression of Anti-Melanoma Differentiation-Associated Gene 5 Antibody. Arthritis Care Res(2012).
Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of Anti-MDA-5 Autoantibodies in Clinically Amyopathic DM/interstitial Lung Disease During Disease Remission. Rheumatology(2012).
Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma Differentiation-Associated Protein 5 Antibody Level Is a Novel Tool for Monitoring Disease Activity in Rapidly Progressive Interstitial Lung Disease With Dermatomyositis. Br J Dermatol(2017).
Mahler M, Fritzler MJ. “Epitope specificity and significance in systemic autoimmune diseases: implications for immunodiagnostics.” Lupus. 2012; 21(7):755-767.